Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29689539
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Top+Antivir+Med
2018 ; 25
(4
): 138-142
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Maximizing the Benefits of HIV Preexposure Prophylaxis
#MMPMID29689539
Buchbinder SP
Top Antivir Med
2018[Apr]; 25
(4
): 138-142
PMID29689539
show ga
Preexposure prophylaxis (PrEP) with tenofovir/emtricitabine (slash indicates
coformulation) is highly effective in preventing new HIV infections. PrEP
efficacy is strongly associated with adherence. In clinical trials, PrEP has been
more effective in men who have sex with men and HIV-serodiscordant heterosexual
couples than in women, likely reflecting pharmacokinetic differences between
levels of tenofovir disoproxil fumarate in vaginal and rectal tissues, and poorer
adherence in studies in women. Current guidelines recommend daily PrEP for men
and women; however, PrEP taken at least 4 days per week for men may be as
effective as daily PrEP, and women must take PrEP 6 to 7 days per week to
maximize efficacy. Data are accumulating on the effectiveness of pericoital PrEP
for men who have sex with men, but it is not yet recommended in the United
States. PrEP is underprescribed for younger individuals, black individuals, and
Hispanic and Latino individuals. This article summarizes a presentation by Susan
P. Buchbinder, MD, at the IAS-USA continuing education program, Improving the
Management of HIV Disease, held in Chicago, Illinois, in May 2017.
|*HIV Infections/drug therapy/prevention & control
[MESH]
free
free
free
